Jupiter Neurosciences wins exclusive U.S. rights to ALA-002

Jupiter Neurosciences said Tuesday it signed a definitive license agreement for perpetual exclusive U.S. rights to ALA-002, a patented MDMA-based candidate with FDA Novel Chemical Entity designation. The deal could be worth up to $100 million and gives the company a second clinical-stage CNS program alongside its Parkinson’s disease asset.

Why it matters: - The agreement turns Jupiter Neurosciences from a single-program biotech into a dual clinical-stage central nervous system developer. - The deal adds a second independent development path alongside JOTROL™, Jupiter Neurosciences’ Phase IIa Parkinson’s disease program. - Jupiter gains perpetual exclusive U.S. rights to a drug candidate with FDA Novel Chemical Entity designation and potential regulatory protection. - The transaction gives Jupiter exposure to U.S. commercialization upside if ALA-002 advances successfully.

What happened: - Jupiter Neurosciences entered a definitive license agreement with PharmAla Biotech Holdings Inc. for ALA-002. - The agreement covers perpetual exclusive U.S. rights to the asset. - Jupiter said the transaction was announced Tuesday and is valued at up to $100 million, including milestone payments and excluding ongoing royalties. - The company said the deal expands its portfolio beyond resveratrol-based JOTROL™.

The details: - The upfront package totals $3.3 million, consisting of $1.5 million in cash and $1.8 million in Jupiter common stock subject to a 120-day lock-up. - Jupiter owes a $3.3 million development milestone when Phase 3 first patient in is reached. - Jupiter owes a $20 million regulatory milestone upon U.S. NDA approval. - Commercial milestones total $10 million, $30 million and $33.3 million at $333 million, $1 billion and $2 billion in cumulative U.S. net sales. - Jupiter will pay a 3% royalty on net sales after the third commercialization milestone. - ALA-002 is a patented, non-racemic MDMA formulation. - The FDA has designated ALA-002 as a Novel Chemical Entity. - The designation can provide enhanced regulatory protection and a five-year data exclusivity period upon approval. - Jupiter said ALA-002 is designed to improve cardiovascular safety and reduce abuse liability compared with racemic MDMA while preserving therapeutic effects used in MDMA-assisted psychotherapy. - PharmAla’s MDMA supply is already active in U.S. government-sponsored VA and DHA clinical trials. - PharmAla will continue manufacturing ALA-002 for Jupiter under commercial terms to be negotiated. - Jupiter said the structure should accelerate development timelines. - Jupiter said the U.S. psychedelic therapeutics market was estimated at $3 billion in 2024 and could grow to $8 billion by 2030, citing Strategic Market Research. - The company said the asset targets treatment-resistant PTSD, anxiety and related neuropsychiatric conditions. - Jupiter linked the deal to an April 18, 2026 executive order on investigational psychedelic therapies. - The order directs the FDA and DEA to expand access through a Right to Try pathway, Commissioner's National Priority Vouchers and $50 million in ARPA-H funding for psychedelic medicine programs. - Jupiter’s management said the regulatory backdrop may support faster development for eligible psychedelic therapeutics. - Management said the company has added two experts to its board, Tomas Philipson and Andrew Cutler, as part of its move into psychedelic medicines. - Jupiter said the next 12 months will be transformative for the company. - Jupiter’s website is more information.

Between the lines: - The deal is as much about strategy as product expansion, giving Jupiter a second clinical-stage asset in a field where financing and trial execution are often the main bottlenecks. - The stock-and-cash structure ties part of the upfront consideration to Jupiter equity, which limits near-term cash outlay but adds dilution risk. - The executive order and regulatory language give the company a policy tailwind, but the asset still faces the usual clinical, regulatory and financing risks. - Jupiter’s comments signal an effort to position the company at the intersection of CNS disorders, neuroinflammation and psychedelic medicine.

What's next: - Jupiter will focus on clinical execution for both ALA-002 and JOTROL™. - The company will need to complete remaining deal steps and satisfy closing conditions. - PharmAla is expected to keep advancing ALA-002 outside the United States. - Future value creation depends on safety, efficacy, regulatory review and financing access.

The bottom line: - Jupiter just bought itself a broader CNS story, but the path to value now runs through clinical data, FDA review and capital discipline.